These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32333714)

  • 41. Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes.
    Hwang ME; Mayeda M; Liz M; Goode-Marshall B; Gonzalez L; Elliston CD; Spina CS; Padilla OA; Wenske S; Deutsch I
    Radiat Oncol; 2019 Aug; 14(1):136. PubMed ID: 31375119
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-cesium: Results of a prospective phase II study.
    Blanchard P; Pugh TJ; Swanson DA; Mahmood U; Chen HC; Wang X; Graber WJ; Kudchadker RJ; Bruno T; Feeley T; Frank SJ
    Brachytherapy; 2018; 17(2):265-276. PubMed ID: 29269207
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel model to correlate hydrogel spacer placement, perirectal space creation, and rectum dosimetry in prostate stereotactic body radiotherapy.
    Hwang ME; Black PJ; Elliston CD; Wolthuis BA; Smith DR; Wu CC; Wenske S; Deutsch I
    Radiat Oncol; 2018 Oct; 13(1):192. PubMed ID: 30285812
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer.
    Hoppe BS; Michalski JM; Mendenhall NP; Morris CG; Henderson RH; Nichols RC; Mendenhall WM; Williams CR; Regan MM; Chipman JJ; Crociani CM; Sandler HM; Sanda MG; Hamstra DA
    Cancer; 2014 Apr; 120(7):1076-82. PubMed ID: 24382757
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Learning curve in the application of a hydrogel spacer to protect the rectal wall during radiotherapy of localized prostate cancer.
    Pinkawa M; Klotz J; Djukic V; Schubert C; Escobar-Corral N; Caffaro M; Piroth MD; Holy R; Eble MJ
    Urology; 2013 Oct; 82(4):963-8. PubMed ID: 24074991
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospective analysis of hydrogel spacer for patients with prostate cancer undergoing radiotherapy.
    Chao M; Ho H; Chan Y; Tan A; Pham T; Bolton D; Troy A; Temelcos C; Sengupta S; McMillan K; Cham CW; Liu M; Ding W; Subramanian B; Wasiak J; Lim Joon D; Spencer S; Lawrentschuk N
    BJU Int; 2018 Sep; 122(3):427-433. PubMed ID: 29520983
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Feasibility of and rectal dosimetry improvement with the use of SpaceOAR® hydrogel for dose-escalated prostate cancer radiotherapy.
    van Gysen K; Kneebone A; Alfieri F; Guo L; Eade T
    J Med Imaging Radiat Oncol; 2014 Aug; 58(4):511-6. PubMed ID: 24580893
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patient-reported quality of life during radiation treatment for localized prostate cancer: results from a prospective phase II trial.
    Chen RC; Zhang Y; Chen MH; McMahon E; Loffredo M; McPherson CP; Nguyen AU; Nguyen PL; D'Amico AV
    BJU Int; 2012 Dec; 110(11):1690-5. PubMed ID: 22502770
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer.
    Gray PJ; Paly JJ; Yeap BY; Sanda MG; Sandler HM; Michalski JM; Talcott JA; Coen JJ; Hamstra DA; Shipley WU; Hahn SM; Zietman AL; Bekelman JE; Efstathiou JA
    Cancer; 2013 May; 119(9):1729-35. PubMed ID: 23436283
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial.
    Bruner DW; Pugh SL; Lee WR; Hall WA; Dignam JJ; Low D; Swanson GP; Shah AB; Malone S; Michalski JM; Dayes IS; Seaward SA; Nguyen PL; Pisansky TM; Chen Y; Sandler HM; Movsas B
    JAMA Oncol; 2019 May; 5(5):664-670. PubMed ID: 30763425
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-Term Quality of Life in Prostate Cancer Patients Treated With Cesium-131.
    Glaser SM; Chen KS; Benoit RM; Smith RP; Beriwal S
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1053-1058. PubMed ID: 28721888
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dosimetric predictors of acute bowel toxicity after Stereotactic Body Radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
    Repka MC; Carrasquilla M; Paydar I; Wu B; Lei S; Suy S; Collins SP; Kole TP
    Acta Oncol; 2023 Feb; 62(2):174-179. PubMed ID: 36826994
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intensity-modulated radiotherapy of prostate cancer with simultaneous integrated boost after molecular imaging with 18F-choline-PET/CT : Clinical results and quality of life.
    Schlenter M; Berneking V; Krenkel B; Mottaghy FM; Vögeli TA; Eble MJ; Pinkawa M
    Strahlenther Onkol; 2018 Jul; 194(7):638-645. PubMed ID: 29511777
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dose-volume histogram parameters and patient-reported EPIC-Bowel domain in prostate cancer proton therapy.
    Bulman GF; Bhangoo RS; DeWees TA; Petersen MM; Thorpe CS; Wong WW; Rwigema JCM; Daniels TB; Keole SR; Schild SE; Vargas CE
    Radiat Oncol J; 2021 Jun; 39(2):122-128. PubMed ID: 34619829
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial.
    Quon HC; Ong A; Cheung P; Chu W; Chung HT; Vesprini D; Chowdhury A; Panjwani D; Pang G; Korol R; Davidson M; Ravi A; McCurdy B; Zhang L; Mamedov A; Deabreu A; Loblaw A
    Radiother Oncol; 2018 May; 127(2):206-212. PubMed ID: 29551231
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy.
    Elias E; Helou J; Zhang L; Cheung P; Deabreu A; D'Alimonte L; Sethukavalan P; Mamedov A; Cardoso M; Loblaw A
    Radiother Oncol; 2014 Jul; 112(1):83-8. PubMed ID: 25005578
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding.
    Lee JY; Daignault-Newton S; Heath G; Scarlett S; Sanda MG; Chang P; Regan MM; Michalski JM; Sandler HM; Feng FY; Kuban DA; Zietman AL; Ciezki JP; Kaplan ID; Crociani C; McLaughlin WP; Mantz CA; Finkelstein SE; Suy S; Collins SP; Garin O; Ferrer M; Hamstra DA; Spratt DE
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(4):770-777. PubMed ID: 27663760
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy.
    Banerji JS; Hurwitz LM; Cullen J; Wolff EM; Levie KE; Rosner IL; Brand TC; LʼEsperance JO; Sterbis JR; Porter CR
    Urol Oncol; 2017 May; 35(5):234-242. PubMed ID: 28110975
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quality of Life after post-prostatectomy intensity modulated radiation therapy to the prostate bed with or without the use of gold fiducial markers for image guidance or higher total radiotherapy doses.
    Abuodeh YA; Naghavi AO; Juan TH; Ma Z; Wilder RB
    Int Braz J Urol; 2017; 43(4):628-637. PubMed ID: 28379660
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Delphi study to identify consensus on patient selection for hydrogel rectal spacer use during radiation therapy for prostate cancer in the UK.
    Payne HA; Jain S; Peedell C; Edwards A; Thomas JA; Das P; Hansson Hedblom A; Woodward E; Saunders R; Bahl A
    BMJ Open; 2022 Jul; 12(7):e060506. PubMed ID: 35858729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.